Cover Image
市場調查報告書

口服避孕藥市場 (產品種 (複合藥丸,單相性藥丸,三相性藥丸及其他),類別 (非專利,品牌藥) 各) - 全球產業分析,規模,構成比,成長率,趨勢及預測:2015-2023年

Oral Contraceptive Pills Market (by Type - Combination Pill, Monophasic Pill, Triphasic Pill, Others; by Category - Generic and Branded) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 350558
出版日期 內容資訊 英文 71 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
口服避孕藥市場 (產品種 (複合藥丸,單相性藥丸,三相性藥丸及其他),類別 (非專利,品牌藥) 各) - 全球產業分析,規模,構成比,成長率,趨勢及預測:2015-2023年 Oral Contraceptive Pills Market (by Type - Combination Pill, Monophasic Pill, Triphasic Pill, Others; by Category - Generic and Branded) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日期: 2015年12月23日 內容資訊: 英文 71 Pages
簡介

口服避孕藥是防黃體素和雌激素荷爾蒙等排卵來避孕之製劑,同時被稱為COCP,產品有服用21日型、服用24日型、服用28日型、91日裝、四相性服用型等五種上市。24日型有Bayer的Yaz及Loestrin、91日裝有Barr Laboratories的Seasonale、 Teva Pharmaceutical Industries的Seasonique、四相性服用型則以Bayer的Natazia非常暢銷。

本報告以口服避孕藥的全球市場為焦點,依各產品類型 (複合藥丸,單相性藥丸,三相性藥丸及其他),類別 (非專利,品牌藥) 及地區 (北美,歐洲,亞太地區,中南美,中東·非洲) 別預測2015-2023年這段期間的交易規模轉變,同時更彙整產業結構,供需趨勢,推動·阻礙因素,機會,競爭環境等分析資訊和主要加入企業簡介。

第1章 序

  • 報告說明
  • 市場區隔
  • 調查方法

第2章 摘要整理

  • 口服避孕藥的全球市場 - 各地區:2014-2023年 (單位:100萬美元)
  • 口服避孕藥的全球市場 - 各產品類型:2014年 (單位:100萬美元)
  • 口服避孕藥市場簡述

第3章 口服避孕藥市場 - 產業分析

  • 簡介
  • 市場推動要素
    • 關係到未滿足需求的高意外妊娠比率
    • 全球行政機關和NGO的認識計劃促進避孕藥的使用
    • 懷孕年齡的提升和增多的高齡生產
  • 阻礙因素
    • 伴隨避孕藥使用的副作用
  • 機會
    • 不同國家的不同倫理·社會問題限制了避孕藥的使用和津貼
    • 亞洲,非洲新興國家存在莫大的避孕未滿足需求
  • 波特的五力分析
  • 市場向心力分析 - 口服避孕藥市場 - 各地區:2014年 (構成比)
  • 熱圖分析 - 主要企業:2014年
  • 引進·處方模式分析
  • 口服避孕藥的市場情形

第4章 市場區隔 - 各產品類型

  • 簡介
  • 口服避孕藥的全球市場收益 - 各產品類型:2013-2023年 (單位:100萬美元)
  • 複合藥丸的全球市場收益:2013-2023年 (單位:100萬美元)
    • 單相性藥丸的全球市場收益:2013-2023年 (單位:100萬美元)
    • 三相性藥丸的全球市場收益:2013-2023年 (單位:100萬美元)
    • 其他複合藥丸的全球市場收益:2013-2023年 (單位:100萬美元)
  • 黃體素單成分口服避孕藥的全球市場收益:2013-2023年 (單位:100萬美元)
  • 其他口服避孕藥的全球市場收益:2013-2023年 (單位:100萬美元)

第5章 市場區隔 - 各類別

  • 簡介
  • 口服避孕藥的全球市場收益 - 各類別:2013-2023年 (單位:100萬美元)
  • 非專利口服避孕藥的全球市場收益:2013-2023年 (單位:100萬美元)
  • 品牌口服避孕藥的全球市場收益:2013-2023年 (單位:100萬美元)

第6章 市場區隔 - 各地區

  • 簡介
  • 口服避孕藥的全球市場收益 - 各地區:2013-2023年 (單位:100萬美元)
  • 北美的口服避孕藥收益 - 各國:2013-2023年 (單位:100萬美元)
  • 歐洲的口服避孕藥收益 - 各國:2013-2023年 (單位:100萬美元)
  • 亞太地區的口服避孕藥收益 - 各國:2013-2023年 (單位:100萬美元)
  • 中南美的口服避孕藥收益 - 各國:2013-2023年 (單位:100萬美元)
  • 中東·非洲的口服避孕藥收益 - 各國:2013-2023年 (單位:100萬美元)

第7章 企業簡介

  • Allergan, plc (Actavis)
  • Bayer AG
  • Janssen Global Services, LLC
  • Mankind Pharma Ltd.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Piramal Enterprises Ltd.
  • Teva Pharmaceutical Industries Ltd
目錄

Oral contraceptive pills are birth control pills including progestin and estrogen hormones. These hormones induce contraception/birth control by preventing ovulation. These pills are also known as combined pills or combined oral contraceptive pills (COCP). Combined oral contraceptive pills are available in five different packs: the 21-day pack, the 24-day pack, the 28-day pack, the 91-day pack and the four-phase regimen. Bayer's Yaz and Loestrin are the most widely preferred brands of the 24-day pack. Barr Laboratories' Seasonale and Teva Pharmaceutical Industries' Seasonique are preferred in the 91-day pack sub-segment. In the four-phase regimen, Bayer's Natazia dominates the market.

Oral contraceptive pills are the most common form of reversible contraception in the developed economies of the world such as the U.S., Canada, the Western Europe and Australia. Their high effectiveness (99.9% when accurately used and 92% when typically used) and convenience in use (in comparison to contraceptive devices, especially implants), drive the oral contraceptive pills segment.

This report provides in-depth analysis of the global oral contraceptives pills market. The stakeholders for this report include companies involved in the research and development, manufacturing and commercialization of oral contraceptive pills, suppliers and new entrants planning to invest in this market. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition for different oral contraceptive pills in the five major regions.

The market overview section of this report analyzes market dynamics such as drivers, restraints and opportunities that influence the oral contraceptive pills market in the current and future scenario. Further, Porter's five forces analysis and market attractiveness analysis have been included in market overview section in order to explain the intensity of competition in the market. Porter's five forces analysis is also elucidated in the section to understand the attractiveness of the oral contraceptive pills market in terms of the five different attributes that have an effect on the sustenance of the players in the oral contraceptive pills market. Competitive scenario among the market players is analyzed through a heat map of major market players in the competitive landscape section of the report. All these factors will help the market players to decide about the business strategies and plans to be incurred in future for strengthening their position in the global market.

Based on the product types, the global oral contraceptives market is segmented into combination pills, progestin only pills and others. Combination pills are further categorized into three segments including monophasic pills, triphasic pills and others. Market revenue in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) from 2015 to 2023 is analyzed for the various types of oral contraceptive pills.

Geographically, the oral contraceptive pills market has been differentiated into five major regions: North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). This section of the report provides with the market estimation in terms of revenue (US$ Mn) of contraceptive pills market in these five regions from 2013 to 2023. Market revenue for oral contraceptive pills is also provided for geographies along with CAGR % for period 2015 to 2023, considering 2014 as the base year.

This report also includes recommendations section that will assist new companies in establishing their presence and market players in expanding their market share in the oral contraceptive pills market. The report concludes with the company profile section which includes company overview, financial overview, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Actavis, Inc., Bayers AG, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.

The global oral contraceptive pills market is segmented into the following categories:

Global Oral Contraceptive Pills Market, by Types

  • Combination
    • Monophasic
    • Triphasic
    • Others
  • Progestin Only
  • Others

Global Oral Contraceptive Pills Market, by Category

  • Generic
  • Branded

Global Oral Contraceptive Pills Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Rest pf APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • Rest of MEA

Table of Contents

Chapter 1 Preface

  • 1.1 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology

Chapter 2 Executive Summary

  • 2.1 Global Oral Contraceptive Pills Market, by Geography, 2014-2023 (US$ Mn)
  • 2.2 Global Oral Contraceptive Pills Market, by Type, 2014 (US$ Mn)
  • 2.3 Oral Contraceptive Pills Market Snapshot

Chapter 3 Oral Contraceptive Pills Market- Industry Analysis

  • 3.1 Introduction
  • 3.2 Market Drivers
    • 3.2.1 High incident rate of unintended pregnancies is leading to unmet contraceptive needs
    • 3.2.2 Awareness programs by government and NGOs are promoting the use of contraceptive pills globally
    • 3.2.3 Increasing maternal age and late pregnancies
  • 3.3 Restraints
    • 3.3.1 Side effects associated with the use of contraceptive drugs
  • 3.4 Opportunity
    • 3.4.1 Ethical and social issues restrict the use or subsidies on contraceptives in some countries
    • 3.4.2 Presence of large unmet contraceptive needs in emerging Asian and African countries
  • 3.5 Porter's Five Forces Analysis
  • 3.6 Market Attractiveness Analysis- Oral Contraceptive Pills Market, by Geography (2014) (%)
  • 3.7 Heat Map Analysis, by Key Players, 2014
  • 3.8 Adoption and Prescription Pattern Analysis
  • 3.9 Market Scenario of Oral Contraceptive Pills

Chapter 4 Market Segmentation - By Type

  • 4.1 Introduction
  • 4.2 Global Oral Contraceptive Pills Market Revenue, by Type, 2013-2023 (US$ Mn)
  • 4.3 Global Combination Pills Market Revenue, 2013-2023 (US$ Mn)
    • 4.3.1 Global Monophasic Pills Market Revenue, 2013-2023 (US$ Mn)
    • 4.3.2 Global Triphasic Pills Market Revenue, 2013-2023 (US$ Mn)
    • 4.3.3 Global Other Combination Pills Market Revenue, 2013-2023 (US$ Mn)
  • 4.4 Global Progestin Only Pills Market Revenue, 2013-2023 (US$ Mn)
  • 4.5 Global Other Pills Market Revenue, 2013-2023 (US$ Mn)

Chapter 5 Market Segmentation - By Category

  • 5.1 Introduction
  • 5.2 Global Oral Contraceptive Pills Market Revenue, by Category, 2013-2023 (US$ Mn)
  • 5.3 Global Generic Oral Contraceptive Pills Market Revenue, 2013-2023 (US$ Mn)
  • 5.4 Global Branded Oral Contraceptive Pills Market Revenue, 2013-2023 (US$ Mn)

Chapter 6 Market Segmentation - By Geography

  • 6.1 Introduction
  • 6.2 Global Oral Contraceptive Pills Market Revenue, by Geography, 2013-2023 (US$ Mn)
  • 6.3 North America Oral Contraceptive Pills Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 6.4 Europe Oral Contraceptive Pills Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 6.5 Asia Pacific Oral Contraceptive Pills Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 6.6 LATAM Oral Contraceptive Pills Market Revenue, by Country, 2013-2023 (US$ Mn)
  • 6.7 MEA Oral Contraceptive Pills Market Revenue, by Country, 2013-2023 (US$ Mn)

Chapter 7 Company Profiles

  • 7.1 Allergan, plc (Actavis)
  • 7.2 Bayer AG
  • 7.3 Janssen Global Services, LLC
  • 7.4 Mankind Pharma Ltd.
  • 7.5 Merck & Co., Inc.
  • 7.6 Pfizer, Inc.
  • 7.7 Piramal Enterprises Ltd.
  • 7.8 Teva Pharmaceutical Industries Ltd
Back to Top